Catalyst Pharmaceuticals

Catalyst Pharmaceuticals
Name	Catalyst Pharmaceuticals
Type	Public
Industry	Pharmaceutical
Founded	2002
Headquarters	Coral Gables, Florida
Key people	Joseph J. Papa; John F. Crowley; Vikas Sinha
Products	FIRDAPSE
Revenue	(see Business Operations and Financials)

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare neuromuscular and neurological disorders. The company has engaged with regulatory agencies such as the Food and Drug Administration and pursued development programs that connect to patient advocacy organizations like the Muscular Dystrophy Association and the Myasthenia Gravis Foundation of America. Headquartered in Coral Gables, Florida, Catalyst has participated in capital markets including the NASDAQ and interacted with healthcare payers such as Centers for Medicare & Medicaid Services stakeholders.

History

Founded in 2002, the company began during an era of expansion in orphan drug development alongside firms such as Genzyme and Alexion Pharmaceuticals. Early strategic decisions involved in-licensing programs and interactions with venture investors linked to institutions like Kleiner Perkins, New Enterprise Associates, and regional incubators. During the 2000s and 2010s, Catalyst negotiated licensing agreements with biotechs and academic centers, collaborating with entities such as University of Miami, Yale University, and clinical research networks including National Institutes of Health trial sites. The company's trajectory included public offerings on exchanges attended by firms like Goldman Sachs and JP Morgan, mergers and acquisitions activity reminiscent of transactions involving Pfizer and Bristol-Myers Squibb, and legal encounters that paralleled cases involving Novartis and Gilead Sciences.

Products and Pipeline

Catalyst's marketed product portfolio is anchored by a treatment for congenital and acquired neuromuscular disorders, developed in the context of therapies similar to those from Biogen, Roche, and Novartis Oncology. Pipeline programs have included small molecules, biologics, and repurposed agents evaluated in clinical trials overseen by committees like the Institutional Review Board at academic centers and conducted in coordination with trial sponsors such as ICON plc and PPD. The company has investigated indications overlapping with work by researchers at Johns Hopkins University, Massachusetts General Hospital, and Mayo Clinic, leveraging endpoints familiar to regulators like the European Medicines Agency and reviewers from the FDA Oncology Center of Excellence.

Business Operations and Financials

Catalyst’s financial operations have involved capital raises on public markets, debt and equity financings underwriters including Morgan Stanley and Citigroup, and commercial partnerships resembling those with Amgen and Sanofi. Revenue recognition and reimbursement dynamics have required engagement with payers such as UnitedHealth Group, Aetna, and federal programs like Veterans Health Administration. Manufacturing and supply-chain arrangements have tied the company to contract manufacturers such as Catalent and distributors akin to McKesson and AmerisourceBergen. Investor relations activities have been influenced by proxy advisory firms like Institutional Shareholder Services and analyst coverage from banks such as J.P. Morgan and Evercore.

Regulatory and Legal Issues

Catalyst has navigated regulatory approvals and labeling discussions with the Food and Drug Administration and pursued orphan drug designations under statutes similar to the Orphan Drug Act. The company has been party to litigation and patent disputes echoing matters involving Teva Pharmaceutical Industries and Amgen, interacting with federal courts including the United States Court of Appeals for the Federal Circuit. Pricing and reimbursement controversies touched stakeholders such as the Centers for Medicare & Medicaid Services and state Medicaid programs, raising debate with advocacy groups like AARP and policy bodies such as the Congressional Budget Office. Compliance topics have involved counsel drawn from firms that have represented companies in matters before the Securities and Exchange Commission.

Research and Collaborations

Research partnerships have connected Catalyst to academic collaborators at University of Pennsylvania, Columbia University, and translational centers like the Broad Institute. Clinical development has employed contract research organizations similar to IQVIA and collaborative networks such as the Rare Diseases Clinical Research Network. The company has worked with patient organizations including the Muscular Dystrophy Association and international patient groups tied to the World Health Organization rare diseases initiatives. Grant and cooperative research agreements have mirrored structures used by entities such as the Bill & Melinda Gates Foundation and the Wellcome Trust in other translational programs.

Corporate Governance and Leadership

Board composition and executive leadership have included directors and officers who have interacted with corporate governance standards advocated by organizations like the Council of Institutional Investors and frameworks promoted by The Business Roundtable. Legal and financial oversight engaged audit firms akin to the Big Four (accounting firms) and general counsel with experience before the Securities and Exchange Commission. Shareholder communications and annual meetings have involved institutional investors such as BlackRock, Vanguard Group, and activist funds similar to those exemplified by Elliott Management in the broader industry.

Category:Pharmaceutical companies